Company Filing History:
1 out of 75 
1 out of 1,974 
Years Active: 2021
Title: Christina Krupka: Innovator in Myeloid Leukemia Treatment
Introduction
Christina Krupka is a notable inventor based in Munich, Germany. She has made significant contributions to the field of medical research, particularly in the treatment of myeloid leukemia. Her innovative approach combines epigenetic factors with bispecific compounds, showcasing her dedication to advancing cancer therapies.
Latest Patents
Christina holds a patent for a groundbreaking invention titled "Combination of epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia." This invention provides a pharmaceutical composition that includes a CD33 targeting compound and at least one epigenetic factor. The epigenetic factors are selected from a group that includes histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors, and All Trans-retinoic acid (ATRA). The invention aims to enhance the responsiveness of patients to CD33 targeting compounds, offering new hope for those affected by this challenging disease.
Career Highlights
Throughout her career, Christina has worked with prominent organizations, including Amgen Research GmbH and Amgen Inc. Her experience in these companies has allowed her to collaborate with leading experts in the field and contribute to significant advancements in cancer treatment.
Collaborations
Christina has collaborated with esteemed colleagues such as Roland B. Walter and Marion Subklewe. These partnerships have further enriched her research and development efforts, leading to innovative solutions in the medical field.
Conclusion
Christina Krupka's work exemplifies the spirit of innovation in the medical research community. Her patent for a combination of epigenetic factors and bispecific compounds represents a significant step forward in the treatment of myeloid leukemia. Through her career and collaborations, she continues to inspire advancements in cancer therapies.